Oncolytics Biotech Secures FDA Alignment for Pivotal Study in Colorectal Cancer — Oncolytics Biotech Inc.

Event summary

Oncolytics Biotech received written FDA feedback aligning on the design of a potential pivotal Part B expansion of the ongoing REO 033 study for second-line RAS-mutant MSS colorectal cancer.
The FDA suggested an End-of-Phase meeting to finalize the registration program, and Oncolytics plans to initiate Part B start-up activities upon positive interim Part A data.
Pelareorep combination therapy has received Fast Track designation from the FDA for this patient population.
REO 033 is evaluating pelareorep in combination with standard-of-care therapy in second-line RAS-mutant, MSS metastatic colorectal cancer.

The big picture

Oncolytics Biotech's alignment with the FDA on the registrational path for pelareorep in second-line RAS-mutant MSS colorectal cancer marks a significant step in the development of this immunotherapy. The potential for accelerated approval based on objective response rate and progression-free survival could expedite the availability of a new treatment option for a challenging patient population. This development comes amid broader industry trends toward combination therapies and the use of immunotherapies to convert 'cold' tumors to 'hot', enhancing anti-cancer immune responses.

What we're watching

Regulatory Pathway: How the FDA's alignment on the accelerated approval pathway will impact the timeline for pelareorep's registration.
Clinical Data: Whether the interim Part A data will support the initiation of the pivotal Part B expansion as planned.
Development Strategy: The pace at which Oncolytics can advance pelareorep in combination with other therapies across multiple solid tumor types.